IL23A and psoriasis: This observation is consistent with prior findings showing a significant decrease in CD103+ T cells in psoriasis-involved skin following treatment with IL - 17A or IL - 23p19 inhibitors (29, 30), suggesting that MSCs may exert similar effects on T-cell migration dynamics (13, 31, 32).